Weekly share tips and analysis: TUI, GSK andBarratt
WEEKLY TIP INSIGHT: 16th FEBRUARY 2019
Weekly Insight: Tipster Scrutiny on TUI, GSK, Smith & Nephew and Thomas Cook
Homebuilders Barratt Developments (BDEV) and RedRow (RDW) also received an influx of tips after both released interim results, while there was increased tip activity for GlaxoSmithKline (GSK) and Smith & Nephew (SN.).
Broker and Tipster Sentiment (Last Seven Days)
It’s been a rough 2019 so far for investors in the travel operator with YTD performance of -26.3%. UBS reiterated its sell rating and target price of £12.00. The broker dropped the target price from £12.00 to £10.90 after last week’s profit warning.
Berenberg offer a contradictory opinion and rate the firm as a buy, with an accompanying target price of £15.00. Shares were trading at £8.26 early on Thursday.
The pharmaceuticals group warned that earnings this year were likely to be hit by rival drugs, but that didn’t stop the positive ratings flooding in.
Barratt Developments (BDEV) announced last week that is plans to pay out special dividends in 2019 and 2020, as it assured investors that “the full year remains in line with the Board’s expectations”.
The news was well-received by brokers and tipsters, despite broker Liberum subsequently downgraded the shares from a buy to a hold.
Peel Hunt was one of several brokers reiterating a positive rating, lifting its target price from £5.10 to £5.75. Shares were trading at £5.64 early on Thursday.
Malcolm Stacey (ShareProphets) was also bullish on the homebuilder’s prospects although G A Chester (The Motley Fool) offered the only negative rating, reaffirming his belief that shares should be avoided.
Smith & Nephew (SN.) shares were up after it published final results on Thursday last week, although brokers and tipsters took a cautious stance. The share price has since dropped following speculation about a $3bn acquisition of US surgical instruments maker NuVasive.
Brokers Exane, JP Morgan, Goldman Sachs and Credit Suisse all published neutral ratings following the release of the medical equipment manufacturers latest numbers. The average target price of those four ratings was £14.68, with shares currently trading almost exactly in line at £14.67.
The travel agent released its first quarter statement last week, and announced that it was conducting a “strategic review” of its airline.
Broker and tipster reception was mixed, but mostly positive. Tipster Chris Bailey (ShareProphets) reiterated a positive outlook on the firm’s future, with HSBC issued a buy rating with a target price of 34p. UBS reiterated a neutral rating with a target price of 32p, while Berenberg consider the shares to be a sell with an accompanying target price of 12p. Shares swapped hands at 28p early on Thursday.
The information in this article is provided by Stockomendation, a multi-award winning Fintech50 platform allowing members access to over 45,000 performance-tracked stock tips. Sign up for FREE at www.stockomendation.com
Disclaimer: The contents of this article should not be considered financial advice. All information correct as at 14th February 2018.
Leave a Reply
You must be logged in to post a comment.